Enhancement of metabolic coronary dilatation by aspirin-like substances by suppression of prostaglandin feedback control?
D000818:Animals; D001241:Aspirin / Q000008:administration & dosage / Q000494:pharmacology*; D002118:Calcium / Q000494:pharmacology; D003331:Coronary Vessels / Q000187:drug effects*; D005246:Feedback; D006339:Heart Rate / Q000187:drug effects; D007213:Indomethacin / Q000008:administration & dosage / Q000494:pharmacology*; D007263:Infusions, Parenteral; D008297:Male; D009638:Norepinephrine / Q000494:pharmacology; D011448:Prostaglandin Antagonists; D011453:Prostaglandins / Q000494:pharmacology; D051381:Rats; D012039:Regional Blood Flow / Q000187:drug effects; D014665:Vasodilator Agents
D011448:Prostaglandin Antagonists; D011453:Prostaglandins; D014665:Vasodilator Agents; D001241:Aspirin; D002118:Calcium; D009638:Norepinephrine; D007213:Indomethacin